Literature DB >> 26756982

Assessment of tumourigenic potential in long-term cryopreserved human adipose-derived stem cells.

Kar Wey Yong1,2, Wan Kamarul Zaman Wan Safwani1, Feng Xu2,3, Xiaohui Zhang2,3, Jane Ru Choi1,2, Wan Abu Bakar Wan Abas1, Siti Zawiah Omar4, Mat Adenan Noor Azmi4, Kien Hui Chua5, Belinda Pingguan-Murphy1.   

Abstract

Cryopreservation represents an efficient way to preserve human mesenchymal stem cells (hMSCs) at early culture/passage, and allows pooling of cells to achieve sufficient cells required for off-the-shelf use in clinical applications, e.g. cell-based therapies and regenerative medicine. To fully apply cryopreserved hMSCs in a clinical setting, it is necessary to evaluate their biosafety, e.g. chromosomal abnormality and tumourigenic potential. To date, many studies have demonstrated that cryopreserved hMSCs display no chromosomal abnormalities. However, the tumourigenic potential of cryopreserved hMSCs has not yet been evaluated. In the present study, we cryopreserved human adipose-derived mesenchymal stem cells (hASCs) for 3 months, using a slow freezing method with various cryoprotective agents (CPAs), followed by assessment of the tumourigenic potential of the cryopreserved hASCs after thawing and subculture. We found that long-term cryopreserved hASCs maintained normal levels of the tumour suppressor markers p53, p21, p16 and pRb, hTERT, telomerase activity and telomere length. Further, we did not observe significant DNA damage or signs of p53 mutation in cryopreserved hASCs. Our findings suggest that long-term cryopreserved hASCs are at low risk of tumourigenesis. These findings aid in establishing the biosafety profile of cryopreserved hASCs, and thus establishing low hazardous risk perception with the use of long-term cryopreserved hASCs for future clinical applications.
Copyright © 2016 John Wiley & Sons, Ltd. Copyright © 2016 John Wiley & Sons, Ltd.

Entities:  

Keywords:  biosafety; clinical applications; human adipose-derived stem cells; long-term cryopreservation; low risk; tumourigenic potential assessment

Mesh:

Substances:

Year:  2016        PMID: 26756982     DOI: 10.1002/term.2120

Source DB:  PubMed          Journal:  J Tissue Eng Regen Med        ISSN: 1932-6254            Impact factor:   3.963


  7 in total

1.  The effects of hypoxia and serum-free conditions on the stemness properties of human adipose-derived stem cells.

Authors:  Wan Kamarul Zaman Wan Safwani; Chin Wei Wong; Kar Wey Yong; Jane Ru Choi; Noor Azmi Mat Adenan; Siti Zawiah Omar; Wan Abu Bakar Wan Abas; Belinda Pingguan-Murphy
Journal:  Cytotechnology       Date:  2016-01-04       Impact factor: 2.058

Review 2.  Effect of hypoxia on human adipose-derived mesenchymal stem cells and its potential clinical applications.

Authors:  Jane Ru Choi; Kar Wey Yong; Wan Kamarul Zaman Wan Safwani
Journal:  Cell Mol Life Sci       Date:  2017-02-21       Impact factor: 9.261

3.  Paracrine Effects of Adipose-Derived Stem Cells on Matrix Stiffness-Induced Cardiac Myofibroblast Differentiation via Angiotensin II Type 1 Receptor and Smad7.

Authors:  Kar Wey Yong; Yuhui Li; Fusheng Liu; Tian Jian Lu; Wan Abu Bakar Wan Abas; Wan Kamarul Zaman Wan Safwani; Belinda Pingguan-Murphy; Yufei Ma; Feng Xu; Guoyou Huang
Journal:  Sci Rep       Date:  2016-10-05       Impact factor: 4.379

Review 4.  Cryopreservation and its clinical applications.

Authors:  Tae Hoon Jang; Sung Choel Park; Ji Hyun Yang; Jung Yoon Kim; Jae Hong Seok; Ui Seo Park; Chang Won Choi; Sung Ryul Lee; Jin Han
Journal:  Integr Med Res       Date:  2017-01-10

5.  Changes in telomere length and senescence markers during human ovarian tissue cryopreservation.

Authors:  Boram Kim; Ki-Jin Ryu; Sanghoon Lee; Tak Kim
Journal:  Sci Rep       Date:  2021-01-26       Impact factor: 4.379

6.  Current Status and Perspectives of Human Mesenchymal Stem Cell Therapy 2020.

Authors:  Jane Ru Choi; Kar Wey Yong; Hui Yin Nam
Journal:  Stem Cells Int       Date:  2022-02-11       Impact factor: 5.443

7.  Cryopreserved Mesenchymal Stromal Cells Maintain Potency in a Retinal Ischemia/Reperfusion Injury Model: Toward an off-the-shelf Therapy.

Authors:  Oliver W Gramlich; Anthony J Burand; Alex J Brown; Riley J Deutsch; Markus H Kuehn; James A Ankrum
Journal:  Sci Rep       Date:  2016-05-23       Impact factor: 4.379

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.